Genzyme Corp. Expands Global Infrastructure with $500 Million Investment

Strategic Insights -

Genzyme Corp. has significantly expanded its global infrastructure for manufacturing and product development through four major projects in Belgium, Ireland, and the United Kingdom. The new and upgraded facilities will support the company's continued growth in the areas of antibody and protein-based medicines. The projects, which have collectively invested over $500 million, include a new biomanufacturing plant in Geel, Belgium, expansion of existing facilities in Waterford, Ireland, and Haverhill, U.K., and creation of an antibody discovery research facility in Cambridge, United Kingdom.

Key Takeaways:

  • Genzyme has invested over $500 million in four major expansion projects in Belgium, Ireland, and the United Kingdom.
  • The projects involve a new biomanufacturing plant in Geel, Belgium, for the production of monoclonal antibodies and proteins.
  • The Geel plant will also produce Myozyme (alglucosidase alfa), an enzyme replacement therapy currently under review for the treatment of Pompe disease.
  • Genzyme's European presence has grown to seven manufacturing sites, including facilities in Belgium, Ireland, the United Kingdom, France, Switzerland, and Germany.
  • The new facilities will support the company's continued growth in antibody and protein-based medicines.
  • Henri A. Termeer, Genzyme's chairman and CEO, stated that the company is pleased to deepen its presence in the European medical and biotechnology community.
  • Genzyme has a significant presence in Europe, with a history of growth and development in the region.

Statistics:

  • Total investment: over $500 million
  • Number of new and expanded facilities: 4
  • Location of new biomanufacturing plant: Geel, Belgium
  • Products to be produced at Geel plant: monoclonal antibodies and proteins, Myozyme (alglucosidase alfa)
  • Number of manufacturing sites in Europe: 7
  • Countries with manufacturing sites: Belgium, Ireland, United Kingdom, France, Switzerland, Germany

Sources:

  • Health & Medicine Week editors
  • NewsRx.com
  • Genzyme Corp. press release